Summary
DexCom, Inc. (DXCM) has filed an 8-K report on January 8, 2024, providing preliminary, unaudited financial results for the fourth quarter and full fiscal year 2023, along with an initial financial outlook for 2024. The company anticipates strong revenue growth, with Q4 2023 revenue expected to reach at least $1.030 billion, a 26% increase year-over-year. For the full fiscal year 2023, total revenue is projected to be around $3.62 billion, marking a 24% increase from 2022. Looking ahead to fiscal year 2024, DexCom has provided an initial revenue outlook, forecasting a total revenue range of approximately $4.15 billion to $4.35 billion. This guidance suggests continued growth for the company in the upcoming year, driven by its diabetes monitoring technologies. Investors should note that these results are preliminary and unaudited, subject to finalization in DexCom's upcoming Form 10-K filing.
Key Highlights
- 1Preliminary Q4 2023 revenue expected to be at least $1.030 billion, a 26% increase year-over-year.
- 2Full fiscal year 2023 preliminary revenue projected at approximately $3.62 billion, a 24% increase from 2022.
- 3Initial 2024 revenue outlook provided, with an anticipated range of $4.15 billion to $4.35 billion.
- 4The company's CEO, Kevin Sayer, will present these preliminary results at the J.P. Morgan 42nd Annual Healthcare Conference.
- 5The reported figures are preliminary and unaudited, subject to finalization in the upcoming Form 10-K.
- 6Forward-looking statements regarding future performance and product launches (like Stelo) are included, with inherent risks and uncertainties.
- 7The filing attaches a press release (Exhibit 99.1) detailing these preliminary results and outlook.